Letter from the Editor

Dear Reader,

I am delighted to introduce you to our ASCO 2021 Annual Meeting congress report.

Expect plenty of new insights in immunotherapy: checkpoint inhibitors may soon be indicated in (neo)adjuvant treatment, and have become the first anti-neoplastic treatment to provide a benefit in the adjuvant treatment of renal cell carcinoma. New immunologic targets (such as LAG-3) continue to enforce treatment options. You may already have known that toxicity somehow rhymes with treatment efficiency; two studies in checkpoint inhibitors seem to confirm this.

Of course, that’s not all there is. HER2 overexpression leads to new treatment options in colorectal cancer. Check out new treatment targets in haematological and solid tumours. The principle of personalised medicine with gene sequencing-based treatment receives further conformation with studies in paediatric cancers.

There’s much more in this report – see for yourself!

Wary of visio-conferences? Me, too! Let’s hope this will be the last entirely virtual ASCO Annual Meeting… Never-ending COVID is no source for optimism, of course. I also hope that the trend to the more economic all-virtual format will not prevail over the advantage to be in the meeting, listen to the expert Q&A, and spend time with attendees to discuss the topics.

Yours, sincerely

Stefan Rauh



Copyright ©2021 Medicom Medical Publishers



Posted on 10 August 202113 August 2021